Clinical

Dataset Information

0

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)


ABSTRACT: This study is a global, multicenter, open-label phase 1b and randomized, double-blinded, 2 part, phase 2 study designed to evaluate the safety and efficacy of rilotumumab or ganitumab in combination with panitumumab versus panitumumab alone in patients with metastatic colorectal cancer whose tumors are wild-type KRAS status.

DISEASE(S): Metastatic Colorectal Cancer,Rectal Neoplasms,Gastrointestinal Neoplasms,Colon Cancer,Gastrointestinal Cancer,Colorectal Cancer,Wild-type Kras Metastatic Colorectal Cancer.---------------------------------------------------------cáncer Colorrectal Metastásico Con Kras No Mutado,Colorectal Neoplasms,Rectal Cancer,Colonic Neoplasms

PROVIDER: 2063797 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| S-EPMC9065471 | biostudies-literature
| S-EPMC4846615 | biostudies-other
| S-EPMC6420784 | biostudies-literature
| S-EPMC7563462 | biostudies-literature
| 2086001 | ecrin-mdr-crc
| 2076338 | ecrin-mdr-crc
| S-EPMC9150132 | biostudies-literature
| 2401536 | ecrin-mdr-crc
| S-EPMC10930734 | biostudies-literature
| S-EPMC9263192 | biostudies-literature